XLock BIOSCIENCES

Novel Biologics for Chemokine Driven Diseases™



XLock Biosciences is a pre-clinical stage biotechnology company overcoming the challenges of chemokine-targeted drug development with protein engineering. The company founders are world experts in chemokine structural biology, immunology and medicine. The company is led by a physician-scientist with two decades of deep Executive level pharmaceutical R&D experience.

OUR FOCUS A fundamental property of the human body is the movement of cells within and between tissues. Cell movement, also known as cell migration, has beneficial effects, for example in wound healing or leukocyte trafficking in infection. Cell migration, however, may have deleterious effects, such as the invasion and metastasis of tumor cells or chronic inflammation. Immune molecules known as chemokines are the prototypical regulator of cell migration. XLock Biosciences seeks to improve human health through the design of new chemokine-targeted therapies and/or treatment strategies to inhibit deleterious cell migration in cancer and inflammation.

XLock Biosciences' lead molecule is focused on the treatment of TH17 driven autoimmune diseases. TH17 diseases include well-treated diseases such as psoriasis and psoriatic arthritis. TH17 driven diseases such as graft versus host disease (GVHD) and especially ocular GVHD (oGVHD), Sjogren's Syndrome and systemic lupus represent unmet TH17-mediated diseases with only minimally effective treatment options. ***It is on these poorly treated TH17 diseases that XLock is focused.*** Most current treatments in TH17 diseases result in broad systemic immune suppression by targeting the *effectors* produced by TH17 cells but not the primary mechanism for TH17 cell recruitment into tissue before they can cause inflammatory damage and disease. XLock is taking an entirely novel approach to the problem of poorly treated TH17 diseases by precisely targeting the TH17 migration receptor CCR6. Our lead molecule, CCL20LD, is a patent protected modification of native CCL20, the sole ligand directing the trafficking of CCR6-expressing TH17 cells. CCL20LD binds to the CCR6 receptor and inhibits the migration of active, disease-causing cells. The benefit of this approach is that CCL20LD is exquisitely selective and should not cause general immune suppression.

OUR SUCCESS TO DATE XLock has proven the efficacy of our lead molecule in multiple animal models of TH17 diseases. This was first demonstrated in preclinical models of psoriasis and psoriatic arthritis where once daily CCL20LD reduced clinical disease signs and symptoms by 90%. Consistent with our strategy, we have recently tested CCL20LD in a mouse model of GVHD. In this model, daily systemic administration of CCL20LD profoundly reduced the number of TH17 cells actively moving into diseased tissues. **This is EXACTLY the response needed for a successful TH-17 targeted therapeutic.**



Reduced TH17 cell recruitment in GVHD. Flow cytometry analysis of liver tissue in no GVHD control mice or mice with chronic GVHD, either untreated (control) or treated with CCL20LD.

WE ARE DRUG DEVELOPERS Our current focus is on meeting the known hurdles for commercial drug development. We understand that great science is necessary — but not sufficient — for successful development of new therapeutics. We have placed significant effort on two key areas that block great science from turning into great therapeutics: CMC and safety/ pharmacology.

First, XLock is able to make CCL20LD at scale, including 200L bacterial fermentation, with very high purity and full biological activity. These methodologies are easily transferrable to a CMO.

Second, a safety pharmacology/toxicology study was performed for XLock by Charles Rivers Laboratories. ***In this study there were NO notable histopathological, hematologic, or clinical chemistry abnormalities found.*** These data support the notion that future studies will find that CCL20LD is safe and effective.

WE ARE PROTECTING OUR ASSETS CCL20LD is protected by *granted* US patent on composition of matter (2019). Additional US provisional applications for methods-of-use in GVHD and other TH17 diseases are pending. The composition of matter patent has been nationalized and *granted* in Australia, Japan, Canada, and Europe with nationalization in Europe to 5 key markets. XLock is the sole assignee of all these patents.

WE ARE FINANCIALLY PRUDENT AND INVESTOR FOCUSED The work of XLock has been funded by $10.92 MM in NIH grants and $5.01 MM in other funding in development grants. ***All funding to date is non-dilutive and there are no obligations or ROFR tied to any of our funding.***

XLock is actively pursuing a Series A funding round

For additional information contact Dr. Bill Clarke, CEO
bill.clarke@xlockbio.com +1 262-501-4800